NCT06525584 Ketamine Infusion as a Method of Cerebral Protection in Children
| NCT ID | NCT06525584 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kemerovo State Medical University |
| Condition | Brain Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 196 participants |
| Start Date | 2023-11-05 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 196 participants in total. It began in 2023-11-05 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is devoted to the use of ketamine infusion in a subanesthetic dose in the postoperative period in children after surgical correction of congenital heart defects in children.
Eligibility Criteria
Inclusion Criteria: * age from 1 to 60 months * body weight from 3.5 to 20 kg * planned surgical intervention to correct a congenital heart defect (atrial or ventricular septal defect) with CPBё * the presence of informed consent for participation in the study signed by the child's legal representative Exclusion Criteria: * lack of informed consent of the patient and parents to participate in the study, * emergency and urgent surgical interventions; * the presence of clinically significant anemia; * hypo-thermic during operation, episodes of desaturation in the perioperative period; * the presence of another congenital heart diseases besides the atrial or ventricular septal defect, as well as their combination; * a history of central nervous system diseases; * an installed pacemaker; * hemodynamic instability requiring preoperative pharmacological and/or mechanical support; * any episodes of cerebrovascular accidents in the history or periop-erative period; * the presence of a patient with severe concomitant diseases that worsen mental and somatic conditio; * acute infection and exacerbation of chronic infection in the perioperative period; * concomitant autoimmune diseases; * the presence of malignant neoplasms; * surgical complications in the postoperative period.
Frequently Asked Questions
Who can join the NCT06525584 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 5 Years, studying Brain Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06525584 currently recruiting?
Yes, NCT06525584 is actively recruiting participants. Visit ClinicalTrials.gov or contact Kemerovo State Medical University to inquire about joining.
Where is the NCT06525584 trial being conducted?
This trial is being conducted at Kemerovo, Russia.
Who is sponsoring the NCT06525584 clinical trial?
NCT06525584 is sponsored by Kemerovo State Medical University. The trial plans to enroll 196 participants.